2019年系统性红斑狼疮研究新进展

doi:10.35541/cjd.20200013

Abstract

Abstract: 【Abstract】 Systemic lupus erythematosus （SLE） is an autoimmune disease that mainly affects young and middle-aged women. It can involve multiple organ systems, with complex and diverse clinical manifestations. The research on the etiology, diagnosis and treatment of SLE has always been a hot spot in this field. In 2019, a lot of new progress was made in the pathogenesis, diagnosis and evaluation, and treatment of SLE in China and other countries, and this review summarizes main representative results.

Key words: Lupus erythematosus, systemic, Receptors, Fc, Programmed cell death 1 receptor, Belimumab

Luo Shuaihantian, Long Hai, Zhang Guiying, Lu Qianjin. Advances in systemic lupus erythematosus in 2019[J]. Chinese Journal of Dermatology, 2021, 54(2): 183-186.doi:10.35541/cjd.20200013

References ［31］

［1］	罗帅寒天, 龙海, 陆前进. 2018年系统性红斑狼疮研究新进展［J］. 中华皮肤科杂志, 2020,53（8）:665⁃667. doi: 10.35541/cjd. 20190298.
［2］	陆前进, 罗帅寒天. 系统性红斑狼疮的诊疗进展［J］. 中华皮肤科杂志, 2018,51（1）:1⁃4. doi: 10.3760/cma.j.issn.0412⁃4030. 2018.01.001.
［3］	Smith KG, Clatworthy MR. FcγRIIB in autoimmunity and infection: evolutionary and therapeutic implications［J］. Nat Rev Immunol, 2010,10（5）:328⁃343. doi: 10.1038/nri2762.
［4］	Hu W, Zhang Y, Sun X, et al. FcγRIIB⁃I232T polymorphic change allosterically suppresses ligand binding［J］. Elife, 2019,8doi: 10.7554/eLife.46689.
［5］	Alsaab HO, Sau S, Alzhrani R, et al. PD⁃1 and PD⁃L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome［J］. Front Pharmacol, 2017,8:561. doi: 10.3389/fphar.2017.00561.
［6］	Han X, Vesely MD, Yang W, et al. PD⁃1H （VISTA）⁃mediated suppression of autoimmunity in systemic and cutaneous lupus erythematosus［J］. Sci Transl Med, 2019,11（522）. doi: 10.1126/scitranslmed.aax1159.
［7］	Honda K, Littman DR. The microbiota in adaptive immune homeostasis and disease［J］. Nature, 2016,535（7610）:75⁃84. doi: 10.1038/nature18848.
［8］	Azzouz D, Omarbekova A, Heguy A, et al. Lupus nephritis is linked to disease⁃activity associated expansions and immunity to a gut commensal［J］. Ann Rheum Dis, 2019,78（7）:947⁃956. doi: 10.1136/annrheumdis⁃2018⁃214856.
［9］	Wu H, Huang X, Qiu H, et al. High salt promotes autoimmunity by TET2⁃induced DNA demethylation and driving the differentiation of Tfh cells［J］. Sci Rep, 2016,6:28065. doi: 10. 1038/srep28065.
［10］	Zhang D, Jin W, Wu R, et al. High glucose intake exacerbates autoimmunity through reactive⁃oxygen⁃species⁃mediated TGF⁃β cytokine activation［J］. Immunity, 2019,51（4）:671⁃681.e5. doi: 10.1016/j.immuni.2019.08.001.
［11］	Nawijn MC, Alendar A, Berns A. For better or for worse: the role of Pim oncogenes in tumorigenesis［J］. Nat Rev Cancer, 2011,11（1）:23⁃34. doi: 10.1038/nrc2986.
［12］	Fu R, Xia Y, Li M, et al. Pim⁃1 as a therapeutic target in lupus nephritis［J］. Arthritis Rheumatol, 2019,71（8）:1308⁃1318. doi: 10.1002/art.40863.
［13］	Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus［J］. Ann Rheum Dis, 2019,78（9）:1151⁃1159. doi: 10.1136/annrheumdis⁃2018⁃214819.
［14］	Kaplan MJ, Radic M. Neutrophil extracellular traps: double⁃edged swords of innate immunity［J］. J Immunol, 2012,189（6）:2689⁃2695. doi: 10.4049/jimmunol.1201719.
［15］	Lood C, Blanco LP, Purmalek MM, et al. Neutrophil extracellular traps enriched in oxidized mitochondrial DNA are interferogenic and contribute to lupus⁃like disease［J］. Nat Med, 2016,22（2）:146⁃153. doi: 10.1038/nm.4027.
［16］	Moore S, Juo HH, Nielsen CT, et al. Role of neutrophil extracellular traps identify patients at risk of increased disease activity and cardiovascular comorbidity in systemic lupus erythematosus［J］. J Rheumatol, 2019. doi: 10.3899/jrheum.19 0875.
［17］	Langefeld CD, Ainsworth HC, Cunninghame Graham DS, et al. Transancestral mapping and genetic load in systemic lupus erythematosus［J］. Nat Commun, 2017,8:16021. doi: 10.1038/ncomms16021.
［18］	Reid S, Alexsson A, Frodlund M, et al. High genetic risk score is associated with early disease onset, damage accrual and decreased survival in systemic lupus erythematosus［J］. Ann Rheum Dis, 2020,79（3）:363⁃369. doi: 10.1136/annrheumdis⁃2019⁃216227.
［19］	Searle SD, Mitnitski A, Gahbauer EA, et al. A standard procedure for creating a frailty index［J］. BMC Geriatr, 2008,8:24. doi: 10.1186/1471⁃2318⁃8⁃24.
［20］	Legge A, Kirkland S, Rockwood K, et al. Evaluating the properties of a frailty index and its association with mortality risk among patients with systemic lupus erythematosus［J］. Arthritis Rheumatol, 2019,71（8）:1297⁃1307. doi: 10.1002/art.40859.
［21］	Wise LM, Stohl W. The safety of belimumab for the treatment of systemic lupus erythematosus［J］. Expert Opin Drug Saf, 2019,18（12）:1133⁃1144. doi: 10.1080/14740338.2019.1685978.
［22］	Wallace DJ, Ginzler EM, Merrill JT, et al. Safety and efficacy of belimumab plus standard therapy for up to thirteen years in patients with systemic lupus erythematosus［J］. Arthritis Rheumatol, 2019,71（7）:1125⁃1134. doi: 10.1002/art.40861.
［23］	Davidson JE, Fu Q, Ji B, et al. Renal remission status and longterm renal survival in patients with lupus nephritis: a retrospective cohort analysis［J］. J Rheumatol, 2018,45（5）:671⁃677. doi: 10.3899/jrheum.161554.
［24］	Blankenship K. GlaxoSmithKline′s benlysta eyes lupus sales boost after kidney trial win［EB/OL］. ［2019⁃12⁃18］. https://www.fiercepharma.com/pharma/glaxosmithkline⁃s⁃benlysta⁃scores⁃trial⁃win⁃patients⁃lupus⁃nephritis.
［25］	Marcus R, Davies A, Ando K, et al. Obinutuzumab for the First⁃Line Treatment of Follicular Lymphoma［J］. N Engl J Med, 2017,377（14）:1331⁃1344. doi: 10.1056/NEJMoa1614598.
［26］	Biogen Inc. Biogen announces positive phase 2 study results for cutaneous lupus erythematosus （CLE） and systemic lupus erythematosus （SLE）［EB/OL］.［2019⁃12⁃3］. http://investors.biogen.com/news⁃releases/news⁃release⁃details/biogen⁃announces⁃positive⁃phase⁃2⁃study⁃results⁃cutaneous⁃lupus.
［27］	Furie RA, Morand EF, Bruce IN, et al. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus （TULIP⁃1）: a randomised, controlled, phase 3 trial［J］. Lancet Rheumatol, 2019, 1（4）: e208⁃e219. doi: 10.1016/S2665⁃9913（19）30076⁃1.
［28］	Morand EF, Furie R, Tanaka Y, et al. Trial of anifrolumab in active systemic lupus erythematosus［J］. N Engl J Med, 2020,382（3）:211⁃221. doi: 10.1056/NEJMoa1912196.
［29］	Furie R, Werth VP, Merola JF, et al. Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus［J］. J Clin Invest, 2019,129（3）:1359⁃1371. doi: 10.1172/JCI124466.
［30］	Roche Inc. FDA grants breakthrough therapy designation for Roche′s Gazyva （obinutuzumab） in lupus nephritis［EB/OL］. ［2019⁃9⁃18］. https://www.roche.com/media/releases/med⁃cor⁃2019⁃09⁃18.htm.
［31］	Mathian A, Pha M, Haroche J, et al. Withdrawal of low⁃dose prednisone in SLE patients with a clinically quiescent disease for more than 1 year: a randomised clinical trial［J］. Ann Rheum Dis, 2020,79（3）:339⁃346. doi: 10.1136/annrheumdis⁃2019⁃216303.

[1]	Yao Manxue, Zhou Naihui. Stevens-Johnson syndrome/toxic epidermal necrolysis associated with programmed death-1/programmed death-ligand 1 inhibitors [J]. Chinese Journal of Dermatology, 2024, 0(3): 20220644-e20220644.
[2]	Shih Yanting, Li Hao, Zheng Jie, Cao Hua. Programmed death-1/programmed death ligand-1 signaling pathway in idiopathic inflammatory myopathies [J]. Chinese Journal of Dermatology, 2022, 55(7): 633-636.
[3]	Zou Meirong, Wang Sheng. Cutaneous immune-related adverse reactions induced by immune checkpoint inhibitors [J]. Chinese Journal of Dermatology, 2022, 55(11): 1026-1030.
[4]	Yu Yingyuan, Li Ying, Yu Zengyang, Zheng Jianfeng, Zhang Xilin, Ding Yangfeng, Shi Yuling, . Efficacy and safety of infliximab in the treatment of severe plaque psoriasis and its effect on the expression of programmed cell death-1 and programmed cell death ligand-1 [J]. Chinese Journal of Dermatology, 2021, 54(7): 590-596.
[5]	Zhang Yuexin, Chen Xixue. Two cases of bullous pemphigoid after long-term treatment with toripalimab [J]. Chinese Journal of Dermatology, 2021, 54(2): 131-135.
[6]	Gao Tianwen, Guo Weinan. Research progress in and new treatment strategies for melanoma in China [J]. Chinese Journal of Dermatology, 2021, 54(1): 27-32.
[7]	Chen Yihe, Luo Dan. Immune checkpoint inhibitor therapy for malignant melanoma [J]. Chinese Journal of Dermatology, 2020, 53(10): 841-845.
[8]	Yang Min, Zhu Yinghua, Peng Linlin, Wang Shujing, Jin Yali. Expression of inducible costimulator and programmed cell death 1 receptor in skin lesions of bullous [J]. Chinese Journal of Dermatology, 2020, 53(10): 813-815.
[9]	Teng ZHU. Expression of programmed cell death 1 receptor and its downstream cytokines in peripheral blood mononuclear cells of patients with generalized pustular psoriasis [J]. Chinese Journal of Dermatology, 2018, 51(6): 451-453.

Advances in systemic lupus erythematosus in 2019

PDF

PDF (Mobile)

Knowledge

Abstract

Cite this article

share this article

References ［31］

Related Articles 9

Metrics

Comments

Recommended 10